Your session is about to expire
← Back to Search
JULUCA 50Mg-25Mg Tablet for HIV/AIDS
Study Summary
This trial will compare how well the drugs in JULUCA work in HIV-negative patients who require hemodialysis, compared to those with normal renal function.
- HIV/AIDS
- Renal Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other documented studies that have explored the efficacy of JULUCA 50Mg-25Mg Tablet?
"Currently, 45 active trial are examining JULUCA 50Mg-25Mg Tablet's efficiency and safety with 16 studies in the third phase. Most of these investigations take place at medical centres located in Durban, KwaZulu-Natal but there is a total 871 clinical sites participating worldwide."
Are individuals under the age of forty able to partake in this clinical experiment?
"The age criteria for participants of this trial is 18 to 65 years. Additionally, there are 125 sub-18 case studies and 420 over-65 investigations being conducted in parallel."
For what afflictions is JULUCA 50Mg-25Mg Tablet recommended?
"JULUCA 50Mg-25Mg Tablet is a suitable treatment for individuals who are naive to HIV-1 therapy, and weigh at least 35 kg."
What is the sample size of this clinical trial?
"Affirmative. According to clinicaltrials.gov, this experiment is in the process of seeking participants. The initial post was made on April 23rd 2021 and recently refreshed on November 6th 2022. Presently, 20 people are needed at one medical center for participation."
Has JULUCA 50Mg-25Mg Tablet been sanctioned by the FDA?
"Our internal assessment of JULUCA 50Mg-25Mg Tablet safety scored it a 3, as its Phase 4 status confirms that the medication has already been approved."
What eligibility criteria are needed to join this research endeavor?
"This medical study is searching for 20 individuals between 18 and 65 years old who suffer from HIV. The most pertinent criteria are the following: Patients must have been on chronic hemodialysis at an established centre for at least 6 months, possess other available venous access points aside from those used for dialysis, be male or female aged 18-65; if known, approximate date of initiation of haemodialysis should also be reported."
Are there any remaining slots available for enrolment in this research?
"Affirmative, the information on clinicaltrials.gov suggests that enrollment for this research project is ongoing. Initially posted on April 23rd 2021 and last amended November 6th 2022, 20 patients are required from a single site."
Share this study with friends
Copy Link
Messenger